Cecilia Brown

DocwireNews

The long-term safety and efficacy profile of tezepelumab in the DESTINATION phase 3 extension trial was consistent with data from the previous PATHWAY phase 2 and NAVIGATOR phase 3 trials, according to an AstraZeneca press release.DESTINATION, a randomized, double-blind, placebo-controlled, long-term extension trial, included patients 12 years and older with severe, uncontrolled asthma. All patients included in DESTINATION completed the 52-week NAVIGATOR or 48-week SOURCE studies comparing tezepelumab plus standard of care with placebo plus standard of care. The patients received treatment with medium- or high-dose inhaled corticosteroids plus at least 1 additional controller medication with or without oral corticosteroids.The primary objective of the DESTINATION trial was to evaluate the long-term safety and tolerability of tezepelumab over a 104-week period, including the treatment period of either NAVIGATOR or SOURCE predecessor studies. The secondary end point was to evaluate the treatment&rsquo;s long-term impact on asthma exacerbations.In patients from the NAVIGATOR study, there was an annualized asthma exacerbation rate reduction of 58% (95% CI, 49-65) in patients treated with tezepelumab plus standard of care over 104 weeks, while the SOURCE study showed an annualized asthma exacerbation reduction of 39% (95% CI, 4-62).The adverse event rates in both studies were lower in patients treated with tezepelumab plus standard of care than in patients treated with placebo plus standard of care.In patients from the NAVIGATOR study, the safety and efficacy data showed the incidence rate of adverse events per 100 patient years was 49.62 in patients who received tezepelumab and 62.66 in patients who received placebo. The serious adverse event rate was 7.85 in patients treated with tezepelumab and 12.45 in patients treated with placebo.In the SOURCE study, the incidence rate of adverse events per 100 patient years was 47.15 in patients who received tezepelumab and 69.97 in patients who received placebo. The incidence rate of serious adverse events per 100 patient years was 13.14 in patients treated with tezepelumab and 17.99 in patients treated with placebo.&ldquo;The results from DESTINATION confirm that the overall long-term efficacy and safety profile for Tezspire is consistent with the previously reported PATHWAY and NAVIGATOR trials and sustained over 2 years,&rdquo; Mene Pangalos, executive vice president, BioPharmaceuticals R&amp;D, said in a press release.

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Long-term Tezepelumab Safety, Efficacy Data Consistent With Earlier Trials

Asthma

The long-term safety and efficacy profile of tezepelumab in the DESTINATION phase 3 extension trial was consistent with data from the previous PATHWAY phase 2 and NAVIGATOR ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe